Metyrapone
- Atc Codes:V04CD01
- CAS Codes:54-36-4#908-35-0
- PHARMGKB ID:54-36-4#908-35-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Dosage
Brand Names
Europe
France: Metopirone; Greece: Metopirone; Ireland: Metopirone; Malta: Metopirone; Netherlands: Metopiron; Sweden: Metopiron; UK: Metopirone.
North America
USA: Metopirone.
Asia
Japan: Metopiron.
Drug combinations
Chemistry
Metyrapone: C~14~H~14~N~2~O. Mw: 226.27. (1) 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-; (2) 2-Methyl-1,2-di-3-pyridyl-1-propanone. CAS-54-36-4 (1963).
Metyrapone Tartrate: C~14~H~14~N~2~O 2C~4~H~6~O~6~. Mw: 526.45. (1) 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2). CAS-908-35-0 (1966).
Pharmacologic Category
Diagnostic Agents; Pituitary Function. (ATC-Code: V04CD01).
Mechanism of action
Therapeutic use
Diagnostic test for hypothalamic-pituitary ACTH function.
Pregnancy and lactiation implications
Use during pregnancy only if clearly needed. Subnormal response may occur in pregnant women and fetal pituitary may be affected. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to metyrapone or any component of the formulation. Adrenal cortical insufficiency.
Warnings and precautions
Might cause CNS depression. Acute adrenal insufficiency may be induced in reduced adrenal secretory capacity. Response to test may be subnormal in hyper-/hypothyroidism.